Alembic Pharma raises Rs 150 crore via NCDs

"The NCD Committee of Alembic Pharma Ltd at its meeting held today has allotted 1,500, 8.37 per cent unsecured listed rated redeemable NCDs of Rs 10,00,000...aggregating to Rs 150 crore under tranche III," the company said in a regulatory filing.

New Delhi: Drug firm Alembic Pharmaceuticals recently said it has raised Rs 150 crore through the allotment of non-convertible debentures (NCDs) on private placement basis. These NCDs carry a coupon rate of 8.37 per cent per annum and are proposed to be listed on NSE.

Also Read: Alembic Pharma JV Aleor gets USFDA nod for Clobetasol Propionate ointment

"The NCD Committee of Alembic Pharmaceuticals Ltd at its meeting held today has allotted 1,500, 8.37 per cent unsecured listed rated redeemable NCDs of Rs 10,00,000...aggregating to Rs 150 crore under tranche III," the company said in a regulatory filing.

Also Read: Alembic Pharma gets USFDA nod for Acetazolamide extended release capsules

Date of maturity of these NCDs is March 18, 2022.

Also Read: Alembic Pharma gets USFDA nod for Olopatadine Hydrochloride ophthalmic solution

Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Vadodara city of Gujarat. Alembic Pharmaceuticals Ltd. is involved in the manufacture of pharmaceutical products, pharmaceutical substances and intermediates.